Pharmaceutical composition for treating hyperuricemia

Abstract

The invention belongs to the field of chemical medicines, and particularly relates to a pharmaceutical composition for treating hyperuricemia. The invention relates to application of a sesquiterpene lactone compound with a structure shown as a formula (I) and pharmaceutically acceptable salts, esters, prodrugs, solvates, polymorphs, hydrates or derivatives of the sesquiterpene lactone compound topreparation of combined drugs for treating the hyperuricemia in combination with hyperuricemia drugs, and further provides the pharmaceutical composition for treating the hyperuricemia. The pharmaceutical composition comprises the compound and one of benzbromarone or lesinurad. The pharmaceutical composition for treating the hyperuricemia can achieve the uric acid reducing effect equivalent to oreven better than that of the drugs for treating the hyperuricemia in the prior art, can obviously reduce the toxic and side effects of the drugs for treating the hyperuricemia in the prior art and improve the safety, and can be used for treating the hyperuricemia and gout or gout complications caused by the hyperuricemia.

Description

Technical field [0001] The invention relates to the field of chemical medicine, in particular to a hyperuricemia pharmaceutical composition. Background technique [0002] In the field of chemical medicine, uric acid is the final metabolite of human purine compounds. Disorders of purine metabolism lead to hyperuricemia. Under a normal purine diet, the fasting blood uric acid level of men is higher than 416μmol / L twice on different days and that of women is higher than 360μmol / L, which is called hyperuricemia. Normally, there is no conscious symptom for simply being in a state of hyperuricemia, but if you stay in this state for a long time, urate in the blood will crystallize and deposit in joints, subcutaneous tissues, kidneys, etc., and then gout and gout will be complicated. A series of clinical manifestations such as disease. According to the recently published "White Paper on China's Gout Status Report 2017", the number of patients with hyperuricemia in my country has reach...

AI Technical Summary

Problems solved by technology

However, with the increase of clinical application of these drugs, their adverse reactions are gradually exposed.

[0004] Benzbromarone is a drug that promotes uric acid excretion. It was launched in France in 1976 and brought a new approach to the treatment of chronic gout. It has a significant effect on the treatment of hyperuricemia, but it can cause gastrointestinal Discomfort, especially diarrhea; it was reported in 2003 that it may cause severe liver damage and was restricted by the European market, and the FDA also rejected its marketing application due to adverse reactions. However, some countries, including my country, still allow its use, but only Decreased uric acid-lowering effect due to administration of drug dosage based on muscle narcotic clearance rate

[0005] Lesinurad, originally developed by AstraZeneca, was launched in the United States in December 2015 and in the European Union in February 2016. Its trade name is Zurampic. It is mainly used in combination with xanthine oxidase inhibitors (such as allopurinol and febuxostat) for the treatment of hyperuricemia associated with gout. Common adverse reactions caused by Lesinurad include headache, flu, increased blood creatinine and gastric Esophageal reflux disease, this product alone will increase the risk of acute renal failure

[0006] The above-mentioned drugs have relatively high toxicity and side effects at conventional doses, and the tolerance of the above-mentioned drugs is generally low, which limits the clinical application of these drugs to a certain extent.

Images